Foamix Pharmaceuticals Ltd Revenue Growth Rates (FOMX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Foamix Pharmaceuticals Ltd   (FOMX)
 

FOMX's Revenue Growth by Quarter and Year

Foamix Pharmaceuticals Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FOMX Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December 0.14
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.31
FY 0.45

FOMXs Annual Revenue
Foamix Pharmaceuticals Ltd 's Revenue in the fiscal year 2019 $ 0.44 millions
Foamix Pharmaceuticals Ltd 's Revenue in the fiscal year 2018 $ 3.60 millions
Foamix Pharmaceuticals Ltd 's Revenue in the fiscal year 2017 $ 3.67 millions
Foamix Pharmaceuticals Ltd 's Revenue in the fiscal year 2016 $ 5.53 millions
Foamix Pharmaceuticals Ltd 's Revenue in the fiscal year 2015 $ 0.85 millions




FOMX Revenue fourth quarter 2019 Y/Y Growth Comment
Foamix Pharmaceuticals Ltd reported drop in Revenue in the fourth quarter 2019 by -84.3% to $ 0.14 millions, from the same quarter in 2018.
The fall in the fourth quarter 2019 Foamix Pharmaceuticals Ltd 's Revenue compares unfavorably to the Company's average Revenue increase of 13.64%.

Looking into fourth quarter 2019 results within Legal Cannabis industry 10 other companies have achieved higher Revenue growth. While Foamix Pharmaceuticals Ltd ' s Revenue meltdown of -84.3% ranks overall at the positon no. 3949 in the fourth quarter 2019.


FOMX Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December -84.3 % -17.31 % -30.2 % 75.29 %
3rd Quarter September - -3.33 % -64.57 % -
2nd Quarter June - 20 % 6.67 % 581.82 %
1st Quarter March -65.93 % -2.15 % 24 % -
FY   -87.64 % -1.91 % -33.63 % -

Financial Statements
Foamix Pharmaceuticals Ltd 's fourth quarter 2019 Revenue $ 0.14 millions FOMX's Income Statement
Foamix Pharmaceuticals Ltd 's fourth quarter 2018 Revenue $ 0.86 millions Quarterly FOMX's Income Statement


FOMX Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - -1.15 % 15.56 % -41.34 %
3rd Quarter September - -9.37 % 12.5 % 238.67 %
2nd Quarter June - 5.49 % -13.98 % 0 %
1st Quarter March -63.95 % -12.5 % -37.58 % -11.76 %
FY (Year on Year)   -87.64 % -1.91 % -33.63 % -


Back to FOMX Growth rate Comparisons >> Back to FOMX Growth rate Comparisons >>


Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #11
Consumer Non Cyclical Sector #158
Overall #3949

Revenue Y/Y Growth Statistics
High Average Low
589.91 % 13.64 % -100 %
(Jun 30 2016)   (Sep 30 2019)
Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #11
Consumer Non Cyclical Sector #158
Overall #3949
Revenue Y/Y Growth Statistics
High Average Low
589.91 % 13.64 % -100 %
(Jun 30 2016)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Foamix Pharmaceuticals Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FOMX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #
Consumer Non Cyclical Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FOMX's IV. Quarter Q/Q Revenue Comment


Foamix Pharmaceuticals Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 3.00 $ 3.60
Y / Y Revenue Growth (TTM) - - - -17.85 % -2.02 %
Year on Year Revenue Growth Overall Ranking # 3638 # 0 # 0 # 3232 # 3640
Seqeuential Revenue Change (TTM) - - - -16.63 % -4.84 %
Seq. Revenue Growth (TTM) Overall Ranking # 3739 # 0 # 0 # 3397 # 2389


Cumulative Revenue growth Comment
Foamix Pharmaceuticals Ltd realized trailing twelve months of $ 0 millions, in the Dec 31 2019, compare to Revenue of $ 4 millions a year ago.

In the Consumer Non Cyclical sector 147 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3638.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 13
Consumer Non Cyclical Sector # 148
Overall # 3638

Revenue TTM Y/Y Growth Statistics
High Average Low
-20.43 %
 -27.46 %
-34.49 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 150
S&P 500 # 3739
Cumulative Revenue growth Comment
Foamix Pharmaceuticals Ltd realized trailing twelve months of $ 0 millions, in the Dec 31 2019, compare to Revenue of $ 4 millions a year ago.

In the Consumer Non Cyclical sector 147 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3638.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 13
Consumer Non Cyclical Sector # 148
Overall # 3638

Revenue TTM Y/Y Growth Statistics
High Average Low
-20.43 %
-27.46 %
-34.49 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 150
S&P 500 # 3739




Other Revenue Growth
Legal Cannabis Industry Revenue Growth Trends and Statistics
Consumer Non Cyclical Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FOMX's Revenue Growth Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Dec 31 2019 within Consumer Non Cyclical SectorY/Y Change %Revenue for the quarter ending Dec 31 2019
Philip Morris International Inc -0.05%$ -0.045 millions
American Vanguard Corporation-0.62%$ -0.621 millions
Edgewell Personal Care Company-0.68%$ -0.678 millions
Vector Group Ltd-0.73%$ -0.731 millions
Nomad Foods Limited-0.83%$ -0.829 millions
Willamette Valley Vineyards Inc -0.87%$ -0.874 millions
The Clorox Company-1.63%$ -1.629 millions
Altria Group Inc -1.75%$ -1.750 millions
Nutrien Ltd -1.94%$ -1.940 millions
Fresh Del Monte Produce Inc-1.98%$ -1.979 millions
Kiwa Bio tech Products Group Corp-2.26%$ -2.260 millions
Equator Beverage Company-2.29%$ -2.288 millions
Sanfilippo John B and Son Inc-2.72%$ -2.721 millions
Kellanova-2.83%$ -2.834 millions
Anheuser busch Inbev Sa-4.19%$ -4.193 millions
Farmer Brothers Co-4.55%$ -4.553 millions
Ambev S a -4.62%$ -4.619 millions
Stepan Company-4.64%$ -4.643 millions
Icl Group Ltd -5.13%$ -5.130 millions
China Green Agriculture Inc-5.15%$ -5.147 millions
Kraft Heinz Co-5.28%$ -5.275 millions
Muliang Viagoo Technology Inc -5.34%$ -5.342 millions
South Dakota Soybean Processors Llc-5.56%$ -5.560 millions
Revlon Inc -5.69%$ -5.690 millions
Bunge Global Sa-6.58%$ -6.584 millions
Coty Inc -6.62%$ -6.618 millions
Twinlab Consolidated Holdings Inc -6.63%$ -6.629 millions
Cf Industries Holdings inc -7.33%$ -7.332 millions
Jones Soda Co -7.56%$ -7.564 millions
Usana Health Sciences Inc -9.27%$ -9.272 millions


About Foamix Pharmaceuticals Ltd Revenue Growth Rates (FOMX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.